Two Natural Opioid Peptides Relieve Pain Through Different Brain Pathways

Endomorphin-1 and endomorphin-2 both activate mu-opioid receptors for pain relief, but endomorphin-2 additionally triggers dynorphin release and kappa-receptor activation, creating a dual-pathway analgesic mechanism.

Ohsawa, M et al.·The Journal of pharmacology and experimental therapeutics·2000·Preliminary EvidenceAnimal StudyAnimal Study
RPEP-00609Animal StudyPreliminary Evidence2000RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Endomorphin-2 produces analgesia through both direct mu-opioid receptor activation and indirect dynorphin A release activating kappa receptors via descending pain pathways, while endomorphin-1 uses only the mu pathway.

Key Numbers

How They Did This

Animal study using supraspinal administration of endomorphins with selective receptor antagonists and anti-peptide antibodies to dissect the descending pain control pathways involved.

Why This Research Matters

Understanding that different endogenous opioid peptides engage different pain pathways helps design more targeted analgesics and explains why the body uses multiple opioid peptides.

The Bigger Picture

The body's pain control system uses multiple overlapping pathways for good reason — different pain types may require different combinations of opioid signals. Understanding this complexity enables more precise pain therapy design.

What This Study Doesn't Tell Us

Animal study with supraspinal peptide injection. The relative importance of each pathway for different pain conditions is unknown. Pharmacological dissection uses selective but not perfectly specific tools.

Questions This Raises

  • ?Can endomorphin-2-like drugs provide broader pain relief than pure mu-agonists?
  • ?Does the dual pathway explain endomorphin-2's effectiveness for certain pain types?
  • ?Could targeting the dynorphin pathway complement mu-opioid therapy?

Trust & Context

Key Stat:
Dual pathway Endomorphin-2 uniquely engages both mu and kappa opioid systems for pain relief, while endomorphin-1 uses only the mu pathway
Evidence Grade:
Preliminary animal evidence with detailed pharmacological pathway dissection providing clear mechanistic differentiation between two endogenous opioid peptides.
Study Age:
Published in 2000. Endomorphin pharmacology has been further characterized, with implications for analgesic drug design.
Original Title:
Differential mechanisms mediating descending pain controls for antinociception induced by supraspinally administered endomorphin-1 and endomorphin-2 in the mouse.
Published In:
The Journal of pharmacology and experimental therapeutics, 294(3), 1106-11 (2000)
Database ID:
RPEP-00609

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

Why does the body have multiple opioid painkillers?

Each opioid peptide engages different pathways and receptor combinations. Endomorphin-2's dual mechanism shows how different peptides provide different types of pain relief, allowing the body to tailor its response.

Could this improve pain medication?

Yes. Drugs that mimic endomorphin-2's dual pathway could provide broader, more effective pain relief than current mu-only drugs. This approach might also reduce the tolerance that develops with single-pathway activation.

Read More on RethinkPeptides

Cite This Study

RPEP-00609·https://rethinkpeptides.com/research/RPEP-00609

APA

Ohsawa, M; Mizoguchi, H; Narita, M; Chu, M; Nagase, H; Tseng, L F. (2000). Differential mechanisms mediating descending pain controls for antinociception induced by supraspinally administered endomorphin-1 and endomorphin-2 in the mouse.. The Journal of pharmacology and experimental therapeutics, 294(3), 1106-11.

MLA

Ohsawa, M, et al. "Differential mechanisms mediating descending pain controls for antinociception induced by supraspinally administered endomorphin-1 and endomorphin-2 in the mouse.." The Journal of pharmacology and experimental therapeutics, 2000.

RethinkPeptides

RethinkPeptides Research Database. "Differential mechanisms mediating descending pain controls f..." RPEP-00609. Retrieved from https://rethinkpeptides.com/research/ohsawa-2000-differential-mechanisms-mediating-descending

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.